Core Insights - The company has successfully completed the first dosing of its second-generation glucose kinase activator (GKA) HMS1005 in a Phase Ib multiple ascending dose (MAD) trial in the United States, marking a significant step in its expansion into the overseas diabetes market [1][2] - HMS1005 is designed as a novel molecular entity with improved physicochemical properties, featuring a sustained-release formulation that allows for once-daily dosing, enhancing patient convenience and potentially improving adherence to treatment [1] - Following the successful completion of the Phase Ib trial, the company plans to seek partners to advance the global market development of HMS1005, further solidifying its leading position in the global GKA sector [1] Group 1 - The Phase Ib clinical trial is a critical step for the company in leading the development of innovative diabetes drugs and expanding into overseas markets [2] - The company emphasizes its commitment to the innovation concept of "repairing sensing and reshaping homeostasis," while continuing to explore better treatment options for type 2 diabetes patients [2] - The successful results from previous single ascending dose (SAD) trials have validated the feasibility of a once-daily oral dosing regimen for treating type 2 diabetes patients with obesity [1]
华领医药在美国启动第二代GKA的Ⅰb期临床试验并完成首例受试者入组